Clinical Trials
275
93 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1976
Active, not recruiting
38
13.8%
Completed
93
33.8%
Not yet recruiting
55
20.0%
Recruiting
63
22.9%
Terminated
5
1.8%
Unknown
19
6.9%
Withdrawn
2
0.7%
No approval data available
- A double-blind, placebo-controlled study found THC reduces the brain's ability to enter a highly integrated state linked to efficient communication across brain networks. - Chronic cannabis users showed persistent neuroadaptations even before receiving THC, suggesting their brains had already adapted to daily use. - Both acute and persistent changes closely tracked the brain's CB1 receptor distribution, with chronic use reducing endogenous CB1 receptor availability. - Recovery is understood as another form of neuroplasticity, where the brain must relearn to function without the drug it had come to expect.
- TempraMed Technologies has secured strategic distribution partnerships across the Netherlands, Belgium, Luxembourg, Israel, and Turkey, expanding access to its VIVI temperature-controlled medication storage solutions. - The company's patented VIVI product line represents the only non-powered solution proven to protect temperature-sensitive injectable medications from heat and cold exposure without refrigeration or batteries. - TempraMed completed a successful public listing on Canadian and Frankfurt stock exchanges, raising C$7.4 million to accelerate global expansion and address the critical need for medication temperature protection. - The company launched VIVI Cap Smart, integrating digital health functionality with passive temperature protection to enable real-time tracking of medication compliance and efficacy data.
